Navigation Links
Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
Date:4/20/2009

nsitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure and influenza through our commercial partners, Roche and 3M Health Care respectively.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.

Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R) Influenza A/B Assay and RAMP 200 reader are not yet licensed for clinical use in Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", "goal" and similar expressions, are "forward-looking statements" or "forward-looking information" under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their f
'/>"/>

SOURCE Response Biomedical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Nationwide Foundation Donates $1.7 Million to American Red Cross for Disaster Preparedness and Response and Increased Blood Collections
2. Groundbreaking First Response Spray Now Available in Europe
3. Cigarette smoke may alter immune response in COPD exacerbations
4. Video: New First Response(R) Fertility Test Helps Women Answer the Question: Am I Able to Get Pregnant?
5. Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
6. Response to Association Between Hospital-Reported Leapfrog Safe Practices Scores and Inpatient Mortality, Journal of the American Medical Association (JAMA); April 1, 2009
7. Response Biomedical Corporation Reports 2008 Financial Results
8. Tray-Pak Direct Mailer Garners 21% Response, Design Award
9. 2-day results predict ultimate response to therapy in chronic hepatitis C
10. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
11. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 1Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 4Natural born divers and the molecular traces of evolution 9035 1Natural born divers and the molecular traces of evolution 9035 2Reading the brain without poking it 9033 1Reading the brain without poking it 9033 2Reading the brain without poking it 9033 3Reading the brain without poking it 9033 4Reading the brain without poking it 9033 5